Celldex (CLDX) CEO Anthony Marucci Receives 375,000 Option Grant

What Happened

• Anthony S. Marucci, President & CEO and a director of Celldex Therapeutics (CLDX), was granted a derivative award of 375,000 shares on June 25, 2026. The filing reports an acquisition price of $0.00 (this is an option/award, not an open‑market purchase), so there was no cash traded at grant. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed on time).
• Transaction type/code: A — grant/award of a derivative instrument (option).
• Amount: 375,000 shares (derivative); reported acquisition price $0.00.
• Vesting: 25% vests on June 25, 2027, then the remainder vests in equal quarterly installments over the next 12 quarters (per footnote).
• Plan: Issued under Celldex’s 2021 Omnibus Equity Incentive Plan (per footnote).
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Filing timeliness: Report appears timely (filed within required business-day window).

Context

• This was an equity compensation grant (options/awards), not a market purchase or sale. Such grants are typically part of executive compensation and vest over time; they do not represent immediate stock purchases or proceeds. The award will only convert into owned shares if and when vested and exercised according to its terms.